Celgene Corporation (NASDAQ: CELG) is one of 116 public companies in the “Pharmaceuticals” industry, but how does it contrast to its peers? We will compare Celgene Corporation to related businesses based on the strength of its profitability, institutional ownership, dividends, valuation, analyst recommendations, risk and earnings.

Valuation & Earnings

This table compares Celgene Corporation and its peers revenue, earnings per share (EPS) and valuation.

Gross Revenue EBITDA Price/Earnings Ratio
Celgene Corporation $12.19 billion $4.83 billion 23.98
Celgene Corporation Competitors $8.08 billion $2.63 billion -0.02

Celgene Corporation has higher revenue and earnings than its peers. Celgene Corporation is trading at a higher price-to-earnings ratio than its peers, indicating that it is currently more expensive than other companies in its industry.

Risk & Volatility

Celgene Corporation has a beta of 1.8, meaning that its stock price is 80% more volatile than the S&P 500. Comparatively, Celgene Corporation’s peers have a beta of 0.95, meaning that their average stock price is 5% less volatile than the S&P 500.

Analyst Ratings

This is a summary of current recommendations for Celgene Corporation and its peers, as provided by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Celgene Corporation 1 10 18 1 2.63
Celgene Corporation Competitors 847 3784 6815 185 2.54

Celgene Corporation currently has a consensus target price of $139.77, suggesting a potential upside of 38.42%. As a group, “Pharmaceuticals” companies have a potential upside of 23.04%. Given Celgene Corporation’s stronger consensus rating and higher probable upside, equities analysts plainly believe Celgene Corporation is more favorable than its peers.


This table compares Celgene Corporation and its peers’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Celgene Corporation 27.36% 63.80% 17.45%
Celgene Corporation Competitors -2,859.53% -67.82% -9.13%

Insider & Institutional Ownership

79.4% of Celgene Corporation shares are owned by institutional investors. Comparatively, 43.7% of shares of all “Pharmaceuticals” companies are owned by institutional investors. 1.0% of Celgene Corporation shares are owned by company insiders. Comparatively, 11.9% of shares of all “Pharmaceuticals” companies are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.


Celgene Corporation beats its peers on 12 of the 13 factors compared.

Celgene Corporation Company Profile

Celgene Corporation is an integrated global biopharmaceutical company. The Company, together with its subsidiaries, is engaged in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases through solutions in protein homeostasis, immuno-oncology, epigenetics, immunology and neuro-inflammation. Its commercial-stage products include REVLIMID (lenalidomide), POMALYST/IMNOVID (pomalidomide), OTEZLA (apremilast), ABRAXANE (paclitaxel albumin-bound particles for injectable suspension), VIDAZA, azacitidine for injection (generic version of VIDAZA) and THALOMID (thalidomide). Its clinical trial activity includes trials across the disease areas of hematology, solid tumors, and inflammation and immunology. The Company also markets ISTODAX, which is an epigenetic modifier. The Company is also evaluating AG-221 (enasidenib) in combination with VIDAZA in newly diagnosed acute myeloid leukemia with isocitrate dehydrogenase-2 mutations.

Receive News & Ratings for Celgene Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celgene Corporation and related companies with MarketBeat.com's FREE daily email newsletter.